Innoviva Reports Third Quarter 2024 Financial Results; Highlights Recent Company ProgressBusiness Wire • 11/06/24
Innoviva Specialty Therapeutics to Present New Clinical Data From Its Development Pipeline and Broad Commercial Portfolio at IDWeek 2024Business Wire • 10/15/24
Innoviva Reports Second Quarter 2024 Financial Results; Highlights Recent Company ProgressBusiness Wire • 07/31/24
Innoviva to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceBusiness Wire • 06/03/24
Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company ProgressBusiness Wire • 05/08/24
Innoviva Specialty Therapeutics' Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024Business Wire • 04/24/24
Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with InnovivaPRNewsWire • 03/04/24
Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company ProgressBusiness Wire • 02/29/24
If You Can Only Buy One Biotech Stock in January, It Better Be One of These 3 NamesInvestorPlace • 01/10/24
Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company ProgressBusiness Wire • 11/01/23
Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated GonorrheaBusiness Wire • 11/01/23
Innoviva Specialty Therapeutics Presents New Data on its Critical Care Antibiotic Therapy Portfolio at Infectious Disease Week (IDWeek) 2023Business Wire • 10/11/23
XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in AdultsBusiness Wire • 09/18/23